SHORT COMMUNICATIONClinical factors associated with adverse outcomes in the acute period of management of submassive pulmonary embolismNguyen, Hong T.a,c; Leffers, Patricka; Smotherman, Carmenb; Ferreira, Jason A.aAuthor Information aDepartment of pharmacy, University of Florida Health bCenter for Data Solutions, University of Florida College of Medicine, Jacksonville cDepartment of pharmacy, St. Mary's Medical Center, West Palm Beach, Florida, USA Correspondence to Jason A. Ferreira, PharmD, University of Florida Health, 655 West 8th Street, Clinical Center Basement C-89, Jacksonville, FL 32209, USA E-mail: [email protected] Received 16 June, 2020 Revised 4 December, 2020 Accepted 12 February, 2021 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.bloodcoagulation.com). Blood Coagulation & Fibrinolysis: July 2021 - Volume 32 - Issue 5 - p 335-339 doi: 10.1097/MBC.0000000000001030 Buy SDC Metrics Abstract The majority of patients with intermediate-to-severe submassive pulmonary embolism are hemodynamically stable upon presentation. There is a lack of evidence for the clinical relevance and safety of initially employed therapies in this population. The objective of current analysis was to determine predictors associated with adverse outcomes in submassive pulmonary embolism patients. This was a single-center, retrospective chart review identifying patient characteristics and clinical factors associated with adverse outcomes within the management of patients presenting to the emergency department for submassive pulmonary embolism. A total of 122 admissions for submassive pulmonary embolism were included. Among these patients, 41% (n = 50) of admissions had an adverse outcomes. Fluid volume was associated with adverse events in an incremental manner (odds ratio 2.1, 95% confidence interval, 1.4–3.2). These findings demonstrate a significant incidence of adverse events in patients with submassive pulmonary embolism and an incremental increase in likelihood of adverse events with each liter of fluid. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.